Leerink Partnrs Has Pessimistic Outlook of COGT Q3 Earnings

Key Points

• Leerink Partners reduced their Q3 2025 earnings estimate for Cogent Biosciences from ($0.54) to ($0.55) per share, while also forecasting continued losses through FY2026 before projecting a profit in FY2027.
• Cogent Biosciences recently reported earnings of ($0.53) per share, slightly surpassing analysts' consensus estimate of ($0.55) by $0.02.
• Despite mixed ratings, the company has a current consensus rating of "Moderate Buy" with an average price target of $18.70, indicating a generally positive outlook from analysts.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities researchers at Leerink Partnrs decreased their Q3 2025 earnings per share estimates for Cogent Biosciences in a report released on Tuesday, August 5th. Leerink Partnrs analyst A. Berens now anticipates that the technology company will earn ($0.55) per share for the quarter, down from their prior forecast of ($0.54). The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences' Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.38) EPS, FY2026 earnings at ($1.49) EPS and FY2027 earnings at $0.97 EPS.

A number of other research analysts have also commented on the company. JPMorgan Chase & Co. upped their price target on Cogent Biosciences from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, August 7th. Leerink Partners upped their target price on Cogent Biosciences from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. Wedbush restated a "neutral" rating and issued a $10.00 target price on shares of Cogent Biosciences in a research note on Monday, June 30th. HC Wainwright cut their target price on Cogent Biosciences from $22.00 to $21.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Finally, Robert W. Baird upped their target price on Cogent Biosciences from $7.00 to $9.00 and gave the company a "neutral" rating in a research note on Tuesday, July 8th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.70.

Cogent Biosciences Stock Up 5.5%

Shares of COGT stock traded up $0.60 during trading hours on Friday, reaching $11.53. 541,427 shares of the company's stock were exchanged, compared to its average volume of 2,000,448. Cogent Biosciences has a fifty-two week low of $3.72 and a fifty-two week high of $12.97. The stock has a market capitalization of $1.31 billion, a P/E ratio of -6.48 and a beta of 0.36. The business has a fifty day moving average price of $9.35 and a 200-day moving average price of $7.37.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The technology company reported ($0.53) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.02.

Insider Buying and Selling at Cogent Biosciences

In other news, Director Fairmount Funds Management Llc bought 2,777,777 shares of the stock in a transaction dated Thursday, July 10th. The shares were acquired at an average price of $9.00 per share, with a total value of $24,999,993.00. Following the acquisition, the director owned 9,003,418 shares in the company, valued at $81,030,762. This trade represents a 44.62% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 7.29% of the company's stock.

Institutional Investors Weigh In On Cogent Biosciences

Several large investors have recently made changes to their positions in the company. Rhumbline Advisers grew its holdings in shares of Cogent Biosciences by 20.0% in the 2nd quarter. Rhumbline Advisers now owns 156,517 shares of the technology company's stock worth $1,124,000 after purchasing an additional 26,059 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Cogent Biosciences by 15.7% in the second quarter. Legal & General Group Plc now owns 80,045 shares of the technology company's stock valued at $575,000 after buying an additional 10,878 shares in the last quarter. Ensign Peak Advisors Inc increased its stake in shares of Cogent Biosciences by 162.0% in the second quarter. Ensign Peak Advisors Inc now owns 49,325 shares of the technology company's stock valued at $354,000 after buying an additional 30,500 shares in the last quarter. Creative Planning increased its stake in shares of Cogent Biosciences by 411.5% in the second quarter. Creative Planning now owns 53,675 shares of the technology company's stock valued at $385,000 after buying an additional 43,181 shares in the last quarter. Finally, Candriam S.C.A. acquired a new stake in shares of Cogent Biosciences in the second quarter valued at $3,068,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.